Clinigen Group - Peter George (CEO)

Right Drug Right Patient Right Time Group overview

. Global specialty pharmaceuticals and services business, supplying clinical trial, licensed and unlicensed critical, life saving drugs

. Three distinct operating businesses which benefit from important synergies between them:

− Clinigen CTS – Specialist global supply of drugs for use in clinical trials (comparator & co-meds)

− Clinigen GAP – Global supply of unlicensed or yet to be licensed drugs for unmet patient need in orphan diseases and difficult to treat oncology's, infectious, orphan and other diseases

− Clinigen SP – A portfolio of oncology support and infectious disease medicines. Selectively acquiring further niche, hospital-based or emergency medicines which can be “revitalised”

. Global distribution network serving c.75+ countries and a broad, blue chip customer base of global pharmaceutical/biotech companies and contract research organisations

. Highly profitable, cash-generative business with impressive continuous growth over the past five years

. Good visibility of earnings with significant growth opportunities, both organically and through acquisition

£m 2014 Revenue (£126.6m) 2013 2014 Growth year ended 30 June Sales 122.6 126.6 3%/7.5%

Gross profit 35.1 41.2 17% Gross profit margin (%) 28.6% 32.5% Overheads1 -12.7 -14.4 13%

EBITDA1 (underlying) 22.4 26.8 20% Margin (%) 18.3% 21.2%

2014 Gross profit (£41.2m) Pre tax profit (underlying)1 20.4 23.1 13%

Earnings per share (underlying)2 20.1p 24.5p 22%

Total dividend 2.6p 3.1p 19%

1: Overheads, EBITDA & underlying PBT represent underlying performance and 2014 excludes a non cash share based payment charge of £1.2m and associated NI of £0.6m. 2013 excludes £4.0m exceptional costs and a non-cash share based payment charge of £1.9m both arising wholly as a result of the companies IPO 2: Adjusted earnings per share is based on underlying PAT adjusted to exclude amortisation

• Like for like revenues* up 7.5% • Underlying EBITDA** up 19.8% to £26.8m • Underlying earnings per share** up 22% to 24.5 pence • Final dividend of 2.1 pence per share proposed, bringing the total dividend to 3.1 pence per share (FY13: 2.6 pence per share)

• Specialty Pharmaceuticals (SP) • two further oncology acquisitions, Savene and Ethyol, bringing the total number of products to five • Lifting of Marketing Authorization suspension achieved for Vibativ and product launched

• Clinical Trial Supply (CTS) • gross margins returned to 15% with deeper penetration of customer base

• Global Access Programs (GAP) • 58,000 units of drugs shipped to more than 75 countries, an 87% increase

©* Copyright Like for like Clinigen at CERGroup represents plc. All revenues rights reserved adjusted for stock fill (£3m) in FY13 ,and FY14 stated at FY13 exchange rates Right Drug Right Patient Right Time 3 ** Underlying EBITDA & EPS excludes share based payments and amortisation Operating Businesses

Cancer cells (Campath) Right Drug Right Patient Right Time 4 Acquiring hospital only or emergency medicines and revitalising them

Oncology Support Portfolio • Dexrazoxane - Cardioxane acquired from Novartis in 2013, used for as a cardioprotective drug against anthracycline toxicity and Savene acquired from Norgine in 2014, used to treat extravasation caused by anthracycline treatment - Both started to contribute in FY14 but will complete transition during FY15 - Strong academic and KOL support for Clinigen’s strategy of challenging Article 31 restrictions

• Ethyol - Acquired from AstraZeneca August 2014, it is a cytoprotective drug indicated to reduce the incidence of xerostomia (dry mouth) in patients undergoing radiation treatment for head and neck cancer and to reduce renal toxicity associated with cisplatin in patients with advanced ovarian cancer - Ethyol will start to contribute during FY15

Right Drug Right Patient Right Time © Copyright Clinigen Group plc. All rights reserved Right Drug Right Patient Right Time 155 Infectious Disease Portfolio • Foscavir - Acquired global rights from AZ in 2010 - Anti-viral last line treatment predominantly used for CMV in bone marrow transplant patients - Sales beginning to plateau and going forward will reflect the growth of underlying disease it treats - 2015 will see full effect of key market price increases and launch in South Korea - In-market sales up 4.2% - Foscavir GAP program accounts for 8% of volume and 10.3% of sales from 18 countries

• Vibativ - In-licensed Vibativ from Theravance in 2013, used to treat hospital acquired pneumonia of an MRSA cause - Product launched in European market 19th September - eTest is currently research only, but will be sufficient for launch patient population

Right Drug Right Patient Right Time © Copyright Clinigen Group plc. All rights reserved Right Drug Right Patient Right Time 156 Financial Year 2014 • 21% of revenue, 56% of GP £m • Foscavir currently accounts for 86% (98%) of sales, 12 months ended 30 June 2012 2013 2014 with the dexrazoxane products accounting for 14% Clinigen CTS 58.8 87.8 83.6 • Continued sales growth; total sales up 10.4% with Clinigen GAP 1.6 10.5 16.1 GP up 16.7% Clinigen SP Sales 21.7 24.3 26.9 Sales 82.1 122.6 126.6 • In-market Foscavir sales up 4.2% YoY SP Growth (%) 124% 12% 10.4% • In-market Cardioxane sales as expected • First Savene sales recorded May 2014 Clinigen CTS 10 11.4 12.6 • First Ethyol sales recorded September 2014 Clinigen GAP 0.7 3.9 5.4 • New Foscavir prices agreed Spain & Italy and Clinigen SP GP 18.3 19.8 23.2 general price increase applied for 2015 Gross profit 29 35.1 41.2 • New MA approved in South Korea YoY SP Growth (%) 123% 8% 16.7% Gross Profit Margin (%) 84.4% 81.5% 86.1% • Vibativ – license suspension lifted, EU grade product manufactured, MA reinstated and EU launch 19th Sept • Ethyol – fifth product acquired August 2014

© Copyright Clinigen Group plc. All rights reserved Right DrugRight Right Drug PatientRight Patient RightRight Time Time 7 . The main revenue generator in the group, but lowest GM% at 15% . A successful entry into the US market has generated strong revenue growth . Addressable outsourced market c. $1.5-2.0bn, estimated to grow at 8% over next 3 years . 55% of purchased clinical trial drugs are estimated to be leftover, unused or wasted, due to poor purchasing decisions . Clinigen CTS has sourced more than 3,000 products for circa 1,750 clinical trials in the last four years . Exclusive clinical trial sourcing and supply arrangements with AstraZeneca UK, Accord Generics, Napp and a direct manufacturing relationship with Roche

Blue chip customer base Clinigen CTS top 15 Customers (2011, 2012, 2013 and 2014)

Top 15 customers represent c. 90% of sales % Sales %

Top 15 Customers

© Copyright Clinigen Group plc. All rights reserved RightRight Drug DrugRight Right Patient Patient Right Right Time Time 8 . Top 18 customers have greater than £1m in sales each . Top 19 products have greater than £1m in sales and account for 77% of total sales and 69% of GM . Of these 19, 16 are comparators and 3 co-therapies; 14 are oncology, 2 Hep C, 2 RA and 1 COPD

Drug Indication Sales FY14 Drug Indication Sales FY13 1 MabThera1 Oncology 14.4 Copegus Hep C 11.3 2 Tarceva Oncology 5.8 Arzerra Oncology 9.0 3 Glivec2 Oncology 5.4 Incivo Hep C 7.6 4 Solvadi Hep C 5.5 Nexavar Oncology 6.5 5 Humira RA 5.4 Glivec2 Oncology 6.7 6 Folotyn Oncology 3.7 Folotyn Oncology 3.7 7 Copegus Hep C 3.6 Pegasys Hep C 3.4 8 Nexavar Oncology 2.5 MabThera1 Oncology 6.1 9 Enbrel RA 2.5 Faslodex Oncology 2.4 10 Levact3 Oncology 4.6 Ribavirin Hep C 2.4

* Glivec, Gemcitibine & Imatinib ** MabThera© Copyright& Rituxan Clinigen Group plc. All rights reserved RightRight Drug DrugRight Right Patient Patient Right Right Time Time 9 *** Levact & Treanda • 66% of sales and 31% of GP • Deeper customer presentation £m 12 months ended 30 June 2012 2013 2014  Top 18 customers and top 19 products have Clinigen CTS Sales 58.8 87.8 83.6 greater than £1m in sales Clinigen GAP 1.6 10.5 16.1  Exclusive supply agreements now account Clinigen SP 21.7 24.3 26.9 for 7.5% of sales with addition of Levact to Sales 82.1 122.6 126.6 AZ and Accord agreements YoY CTS Growth (%) 151% 49% -5%

Financial Year 2014 Clinigen CTS GP 10 11.4 12.6 • Sales down (-£4.2m) due to prior year one-off Clinigen GAP 0.7 3.9 5.4 anti-viral sales (£24m) not repeated Clinigen SP 18.3 19.8 23.2 Gross profit 29 35.1 41.2 • Gross profit performance, up 10.9% at 15.1% YoY CTS Growth (%) 64% 14% 11% • Underlying activity up, with requests up 44% Gross Profit Margin (%) 17.0% 13.0% 15.1% and medicines supplied up 28% • Sales pipeline strong @ c.£160m

© Copyright Clinigen Group plc. All rights reserved RightRight Drug DrugRight Right Patient Patient Right Right Time Time 10 . Clinigen is an early entrant into this new market sector and shows continued strong sales and profit growth

. Compassionate use . Early access to drugs before regulatory approval . Treatment Investigational New Drug programs (US) . Non-launch market access (commercial access) . Mature product access programs to licensed drugs in process of being withdrawn from market

. Often run in orphan or infectious diseases or oncology programs. Exclusive programs under management for clients including, Pfizer, Sanofi, AZ, Boehringer Ingleheim, Astellas and Eisai

. Enable companies to provide market access to medicines before obtaining regulatory approval, in non-launch markets or continue to provide a drug after discontinuation or withdrawal

. Global logistical network, relationships with Key Opinion Leaders, and regulatory expertise key to provide a comprehensive solution to program management

. Growth opportunities in pharmerging markets for “on-demand” unlicensed supply

© Copyright Clinigen Group plc. All rights reserved Right Drug Right Patient Right Time 1115 Company Product Disease Area Astrazeneca CAZ-AVI Complicated intra-abdominal infections Metreleptin Lipodystrophy GAP delivered 58,000 units in FY14 (31,000 FY13) Astellas Enzalutimide Prostate Cancer Xtandi Prostate Cancer Advagraf Transplant Immunosuppressant Modigraf Transplant Immunosuppressant Dificlir Antibacterial Boehringer Ingleheim Nintedanib Idiopathic pulmonary fibrosis BTG Digifab Digoxin Toxicity Voraxase Methotrexate Toxicity UTA 5-FU Toxicity Pfizer Mylotarg Acute Myloid Leukaemia Valeant Demser Malignant Phaeochromocytoma Cuprimine Wilson's Disease Edecrin Nephrotic Syndrome Ethacrynate Sodium Oedema Mephyton Blood Clotting Factors ● Extended Access/Non-launch markets Lacrisert Dry Eye Therapy ● Early Access Cubist Ceftolozane Novel Cephlosporin for cUTIs Abiogen Nerixia Osteogenesis Imperfecta (OI) ● Mature Access Raptor Procysbi Nephropathic Cystinosis Viropharma Plenadren Addisons Disease Zogenix Sumavel Neurology Pharmaxis Bronchitol Cystic Fibrosis Sucampo Amitiza Oncology Support Sanofi Campath Chronic Lymphatic Leukaemia Brabant Brabafen Dravet Syndrome (Epilepsy) Taiho TAS-102 Colorectal Cancer Iron Tx ST10 Iron Deficient Anaemia Eisai Fycompa Epilepsy Clinigen Cardioxane Oncology Support Ethyol Oncology Support Foscavir BMT Vibativ HAP Savene Oncology Support Index Pharmaceuticals Kapaproct Dravet Syndrome (Epilepsy)

th ©Source: Copyright GAP Business Clinigen unit 5GroupJuly 2012 plc. All rights reserved Right Drug Right Patient Right Time 1312 • Continued growth in activity with units £m supplied up 87% 12 months ended 30 June 2012 2013 2014 • Good growth from long-term programs, Clinigen CTS 58.8 87.8 83.6 Campath (+100%) and BTG (+60%) Clinigen GAP Sales 1.6 10.5 16.1 • New client wins; AZ, BI, Taiho and Cubist Clinigen SP 21.7 24.3 26.9 Sales 82.1 122.6 126.6 • Wind-down of a large early access program YoY GAP Growth (%) -16% 559% 54% (enzalutimide) Clinigen CTS 10 11.4 12.6 Financial Year 2014 Clinigen GAP GP 0.7 3.9 5.4 Clinigen SP 18.3 19.8 23.2 • Significant sales growth, up 54% Gross profit 29 35.1 41.2 • Strong gross profit performance, up 33% YoY GAP Growth (%) -42% 467% 39% • ‘Cliniport’ an on-line management support Gross Profit Margin (%) 43.3% 37.3% 33.4% tool live for all programs

MRSA (Vibativ) Right Drug Right Patient Right Time 14 Key Strategic Objectives

SO 1: Acquisition of product opportunities from top 50 pharma

SO 2: Revitalize acquired assets

SO 3: Extend global capabilities

SO 4: #1 Global CTS Company

SO 5: #1 Global GAP Company

SO 6: Corporate Acquisitions

© Copyright Clinigen Group plc. All rights reserved Right Drug Right Patient Right Time 15 SO 2: Revitalize acquired assets Foscavir is an example of what can be achieved (five-fold growth), the dexrazoxane assets have similar opportunities for revitalization

PSUR & ANSM Article 31 meetings

Cardioxane US launch

Broader indication Dexrazoxane

Combipack?

Savene Pricing

Central vs decentralized license

© Copyright Clinigen Group plc. All rights reserved Right Drug Right Patient Right Time 16 Clinigen currently controls its global product supply through a complex network of partners. Strengthening our market presence SO 3: Extend global capabilities and directly serving key growth markets for all three operational businesses is a key strategy

Partner Country

Hospira USA

CPDN Canada

Technofarma South & Latin America

IMS Medical Russia

Proreo Pharma Switzerland

MegaPharm Israel

BL&H South Korea

Zuellig Singapore & Asia

Nobel Pharma Japan

Clinect Australia & NZ

Senaru India

. Unique business model, supplying critical life saving, hospital-based and emergency medicines, both licensed and unlicensed, into c. 75+ countries via a global distribution (hub and spoke) network

. Highly profitable and cash generative business with a impressive track record of significant growth

. Good visibility of earnings with significant growth opportunities, both organically and through acquisition

Right Drug Right Patient Right Time 19 Operating business overviews

focuses on acquiring global rights to niche hospital only drugs or emergency medicines Clinigen SP uses the relationships and insights • SP has had strong growth with good margins which makes it the largest gained from late stage product withdrawals contributor to Gross Profit and non-launch market access programs run • SP currently has five products in its portfolio; two anti-infective products, by GAP to identify potential candidates for Foscavir® and Vibativ® and three oncology support products, acquisition or in-licensing Cardioxane®, Savene® and Ethyol® • New product identification and in-licensing or acquisition of new products is an important strategic element for Clinigen, with the goal of Clinigen CTS and GAP benefit from 10 products by end 2018 Clinigen SP’s experience of regulatory, pharmacovigilance and quality has an 11 year history in clinical and comparator trial drug systems required as a specialty sourcing. CTS is the largest sales contributor with strong pharmaceutical company historical growth. • The market is c.$2bn per annum and Clinigen is the number two ranked specialist company globally for outsourced clinical trial drug supply • The strategic goal is to be the leading global company by 2018

plays an important role in linking the three businesses and ensuring synergies are realised across the Group due to its role in pre-launch, unlicensed supply and withdrawal medicines Clinigen GAP provides on-going patient • GAP has successfully transformed from a UK Specials business to a access to comparator drugs following provider of exclusive Global Access Programs their clinical trial. GAP benefits from • GAP has been instrumental in identifying product acquisition candidates relationships in the clinical trial market • GAPs focus is on extending its global supply and distribution network gained by Clinigen CTS

Discovery & Pre-Clinical Clinical Development Regulatory & Marketing Supply

Services Products

Lead selection & optimization Phase III/IV Phase I Phase II Mature & followed by development clinical trials & Pre marketing Post marketing Clinical Clinical Patent expiry discontinued formulation and pre-clinical post marketing launch & support supply Trials Trials products studies surveillance

Global Access Programs (GAP)

Global Trials Supply (CTS) Specialty Pharmaceuticals (SP)

• Global supply of medicines for use in • Global Access Programs allow critically ill • Acquiring or in-license niche, hospital- phase II to IV clinical trials patients access to unlicensed but based drugs divested by large • Diversified, blue chip customer base potentially life saving treatments pharmaceutical companies with potential with many of the global top 20 • Enable companies to provide market to revitalize with respect to price, pharmaceutical companies and CRO’s as access to medicines before obtaining geography and/or other indications its customers regulatory approval and/or in non-launch • Five products in existing portfolio • Has sourced more than 3,750 products markets or continue to provide a drug • Active pipeline of potential product for circa 2,500 clinical trials in the last after discontinuation or withdrawal acquisitions from global top 50 four years • Most often run in orphan or infectious pharmaceutical companies • Relationships developed through diseases or oncology programs • High profitability with FY2014 gross profit Clinical Trials Supply underpin product • Exclusive programs under management margin of 86% sourcing for Global Access Programs and for clients including Pfizer, Sanofi, GSK, • Strong in-house experience of regulatory, distribution for Specialty Boehringer-Ingelheim, Eisai, BTG and pharmacoviligance and quality systems Pharmaceuticals Astellas • Benefits from Clinical Trials Supply • Relationships and insights from late stage relationships with major pharmaceutical product withdrawals support companies and insights gained from GAP identification of potential product late stage product withdrawals acquisitions for Specialty Pharmaceuticals

Peter George – Chief Executive Officer . Joined Clinigen when it formed in June 2010 . Former CEO at Penn Pharma, having led a GBP67m management buy-out (2007) . Previously executive VP for Wolters Kluwer Health with responsibility for Europe/Asia Pacific regions . Former Chief Operating Officer of Unilabs Clinical Trials International Limited Robin Sibson – Chief Financial Officer . Joined ADL Healthcare Limited, a company owned by Clinigen’s former Executive Chairman (2003) . Over 30 years’ experience in the pharmaceutical industry, including 15 years as Finance Director . Formerly Finance Director of BASF’s UK Pharmaceuticals, sales and R&D divisions . Previously Finance Director at Boots UK Pharmaceutical business, leading the integration following its sale to BASF Shaun Chilton – Chief Operating Officer . Joined Clinigen in January 2012 . Previously President within KnowledgePoint360 Group, a global pharmaceutical information and services operation . 20 years’ commercial, strategic and operational experience, including sales and marketing in Pfizer and Sanofi-Aventis (now Sanofi) Paul Thomas – Chief Technical Officer . Joined Clinigen as consultant in early 2011, permanently appointed in April 2012 . Previously Chief Scientific Officer at Penn Pharma . More than 25 years’ experience in the pharmaceutical industry, having held senior quality assurance and manufacturing posts at Parke-Davis/Warner Lambert and Nycomed-Amersham (GE Healthcare)